Filter Results
:
(502)
Show Results For
- All HBS Web (502)
- Faculty Publications (365)
Show Results For
- All HBS Web (502)
- Faculty Publications (365)
- Web
Climate Impact - Business & Environment
production of next-generation ingredients. We leverage biotechnology as a scalable, sustainable alternative to industrial agriculture and recently launched Palmless , the platform for sustainable palm oil...
View Details
- Web
Winners & Runners-up - New Venture Competition
Track Runner-Up Acillix will deliver on the promise of biotechnology by revolutionizing the water treatment industry with our patented, low cost, environmentally friendly process for water demineralization....
View Details
Joey Ryu
Joey (Won Jung) Ryu is a doctoral student in the Strategy unit at Harvard Business School. Her primary interests are strategic management, economics of innovation and entrepreneurship. Prior to joining HBS, Joey recieved her master's degree from Cornell University...
View Details
- Web
Informa (In Vivo, MedTech Insight, Scrip) | Baker Library | Bloomberg Center | Harvard Business School
platform. Related Resources Medical Devices Pharmaceuticals Database AttributesCoverageIn Vivo - latest 3 months; MedTech - Most recent 1 year(s) 6 month(s) available; Start-up?Categories Industry Specific Databases View Details
- February 2014
- Case
BGI: Data-driven Research
By: Willy Shih and Sen Chai
BGI has the largest installed gene-sequencing capacity in the world, and to Zhang Gengyun, general manager of the Life Sciences Division, this represented an opportunity to apply his training as a plant breeder and his early career work as a biochemist to improving...
View Details
Keywords:
Genomics;
Gene Sequencing;
Life Sciences;
Plant Breeding;
Human Genome Program;
Beijing Genomics Institute;
BGI;
Rice Genome;
Technological Innovation;
Innovation Strategy;
Research;
Research and Development;
Science;
Genetics;
Science-Based Business;
Strategy;
Commercialization;
Corporate Strategy;
Information Technology;
Applications and Software;
Agriculture and Agribusiness Industry;
Agriculture and Agribusiness Industry;
Agriculture and Agribusiness Industry;
China;
United States
Shih, Willy, and Sen Chai. "BGI: Data-driven Research." Harvard Business School Case 614-056, February 2014.
- Web
Student Spotlight: 2023 HCC Co-Presidents Reflect on Their Time at HBS and the Current Health Care Systems - Blog: Health Supplement
how social determinants of health play such a significant role in health outcome disparities for different populations. What industry of health care are you most interested in? I am most interested in digital health and biotechnology....
View Details
- Web
VitalLaw | Baker Library | Bloomberg Center | Harvard Business School
Areas, Tax - Estates, Gifts & Trusts. HBS users, use Capital Changes for access to Practice Areas, Tax - Estates, Gifts & Trusts This database is licensed for academic use only. No commercial use is allowed. Related Resources View Details
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it...
View Details
Keywords:
Patents;
Lawsuits and Litigation;
Rights;
Competitive Strategy;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Innovation;
Funding Model;
Venture Capital;
Partners and Partnerships;
Financing and Loans;
Investment Funds;
Acquisition;
Philanthropy and Charitable Giving;
Biotechnology Industry;
Biotechnology Industry;
San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- 21 Apr 2009
- First Look
First Look: April 21, 2009
institutional theory, and economic theory. Download the paper: http://www.hbs.edu/research/pdf/08-025.pdf Broadening Focus: Spillovers and the Benefits of Specialization in the Hospital Industry Authors:Jonathan R. Clark and Robert S....
View Details
Keywords:
Martha Lagace
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to...
View Details
Keywords:
Product Development;
Marketing Strategy;
Health Testing and Trials;
Risk and Uncertainty;
Technological Innovation;
Innovation Strategy;
Science-Based Business;
Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- 31 Jan 2014
- News
Body, Heal Thyself
breakthrough in] the biotech industry takes a lot of time; it takes a lot of money; it's complicated science." And it takes a lot of people—from scientists to executives to board members. Bancel admits that people see the potential fairly...
View Details
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
Keywords:
Mergers and Acquisitions;
Value;
Valuation;
Judgments;
Decision Making;
Cash Flow;
Financial Instruments;
Cognition and Thinking;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
ubingruo New research finds that large pharmaceutical companies, typically conservative in their pursuit of novel drug development, are more willing to undertake radical innovation after receiving an unexpected cash windfall. The pharmaceutical View Details
- 20 Sep 2021
- Blog Post
Student Spotlight: Summer Internships in Business and Environment
durations, and dispatch it as electricity on demand. Cal's role prior to HBS was an Aerospace Industry Application Engineer at Mathworks. Aditya Desai (MBA 2022, Section J), Summer Internship: MBA Summer Intern at Natron Energy Natron...
View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing...
View Details
Keywords:
Venture Capital;
Business Startups;
Entrepreneurship;
Investment;
Business Strategy;
Financial Services Industry;
Financial Services Industry;
United States;
Ohio
Gompers, Paul A., and Alicia Dadlani. "Drive Capital: A New Road for Venture." Harvard Business School Case 823-056, April 2023.
- January 2014 (Revised June 2015)
- Case
Amgen Inc.: Pursuing Innovation and Imitation? (A)
By: Ian W. Mackenzie
Set in 2009, the (A) case explores whether Amgen, a leading innovator of biotech-based drugs, should enter the emerging business of biosimilars (BS), which are essentially 'me-too' products. There appear to be sound reasons to explore this related diversification:...
View Details
Mackenzie, Ian W. "Amgen Inc.: Pursuing Innovation and Imitation? (A)." Harvard Business School Case 714-424, January 2014. (Revised June 2015.)
- 12 Oct 1999
- Research & Ideas
Porter’s Perspective: Competing in the Global Economy
you decide to put together this collection of articles? Porter In retrospect, my work divides into three major areas. The first has to do with how firms compete in industries and gain competitive advantage. The next focuses on locations...
View Details
Keywords:
Re: Michael E. Porter
- October 2004 (Revised March 2005)
- Case
Langer Lab, The: Commercializing Science
By: H. Kent Bowen, Alex Kazaks, Ayr Muir-Harmony and Bryce LaPierre
Professor Robert Langer's laboratory at MIT is the source of an unusually large number of published papers, patents, and technology licenses to start-up and established companies in the biomedical industry. Explores Langer's leadership and other factors that create a...
View Details
Keywords:
Entrepreneurship;
Technological Innovation;
Business Startups;
Research and Development;
Patents;
Innovation Leadership;
Science-Based Business;
Commercialization;
Biotechnology Industry;
Biotechnology Industry
Bowen, H. Kent, Alex Kazaks, Ayr Muir-Harmony, and Bryce LaPierre. "Langer Lab, The: Commercializing Science." Harvard Business School Case 605-017, October 2004. (Revised March 2005.)